Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration

Abstract

In this analysis of brolucizumab IVI for nAMD, VA remained stable, with a reduction in central subfield thickness. Intraocular inflammation events ranged from mild with spontaneous resolution to severe occlusive retinal vasculitis in 1 eye.